Manufacturers Life Insurance Company, The Prometheus Biosciences, Inc. Transaction History

Manufacturers Life Insurance Company, The

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.0 - $199.92 $0 - $6.46 Million	-32,327 Closed	0 $0
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $988,663 - $1.21 Million	9,556 Added 29.56%	41,883 $4.49 Million
Q4 2022 Aug 11, 2023	BUY	$36.06 - $117.21 $581,287 - $1.89 Million	16,120 Added 99.46%	32,327 $3.56 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $581,287 - $1.89 Million	16,120 Added 99.46%	32,327 $3.56 Million
Q3 2022 Aug 11, 2023	BUY	$28.17 - $59.01 $120,652 - $252,739	4,283 Added 35.92%	16,207 $956,000
Q3 2022 Nov 03, 2022	BUY	$28.17 - $59.01 $120,652 - $252,739	4,283 Added 35.92%	16,207 $950,000
Q2 2022 Aug 11, 2023	SELL	$22.39 - $38.94 $2,664 - $4,633	-119 Reduced 0.99%	11,924 $336,000
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $2,664 - $4,633	-119 Reduced 0.99%	11,924 $337,000
Q1 2022 Aug 11, 2023	SELL	$30.13 - $50.0 $899,079 - $1.49 Million	-29,840 Reduced 71.25%	12,043 $454,000
Q1 2022 May 20, 2022	SELL	$30.13 - $50.0 $82,797 - $137,400	-2,748 Reduced 18.58%	12,043 $455,000
Q4 2021 Feb 16, 2022	BUY	$22.28 - $39.54 $329,543 - $584,836	14,791 New	14,791 $585,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.